Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: Comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist

Kawata, Takayuki; Daimon, Masao; Hasegawa, Rei; Teramoto, Kiyomi; Toyoda, Tomohiko; Tai, Sheng; Yamamoto, Kyohei; Uchida, Daigaku; Himi, Toshiharu; Yoshida, Katsuya; Komuro, Issei

doi:10.1016/j.ahj.2005.09.014

Cited by 34 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a small randomized trial of type 2 diabetes patients, coronary fl ow velocity reserve improved after treatment with an ACE inhibitor but not with an angiotensin-II receptor antagonist, suggesting that ACE inhibition might have benefi cial effects on coronary microangiopathy associated with type 2 diabetes (Kawata et al 2006). In an experimental model of diabetes, this condition was associated with decreased myocardial capillary supply, which was reversed by ACE inhibition, but not by endothelin-1 receptor blockade.…”

Section: Diabetic Patients With Leftventricular Dysfunction After MImentioning

confidence: 94%

Update on the use of Trandolapril in the management of cardiovascular disorders

Díaz

Ducharme²

2008

VHRM

View full text Add to dashboard Cite

Abstract:Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objectives of this article are to review the pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical relevance in cardiovascular medicine. Various populations have been studied in large clinical trials including patients with congestive heart failure (CHF) after an acute myocardial infarction (AMI), diabetics, patients with hypertension (HTN), stable coronary artery disease (CAD) and prevention of proteinuria. Long-term treatment with trandolapril in patients with reduced left ventricular function soon after AMI signifi cantly reduced the risk of overall mortality, mortality from CV causes, sudden death, and the development of severe CHF. Treatment with trandolapril after AMI complicated by left ventricular dysfunction appears to be of considerable importance in patients with diabetes mellitus by saving lives and substantially reducing the risk of progression to severe CHF as well. Moreover, trandolapril reduces progression to proteinuria in high-risk patients. Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum of patient populations studied, the well established dosage and its proven trough-to-peak effect ratios permitting a safe once-a-day administration.

show abstract

Section: Diabetic Patients With Leftventricular Dysfunction After MImentioning

confidence: 94%

Update on the use of Trandolapril in the management of cardiovascular disorders

Díaz

Ducharme²

2008

VHRM

View full text Add to dashboard Cite

show abstract

“…There is considerable evidence to suggest that insulin resistance and hyperglycemia, acting via oxidative stress, inflammation, and advanced glycation end products, can induce microvascular abnormality [21] causing increased microvascular permeability in diabetes [22]. Several studies have shown impaired coronary flow reserve in diabetic individuals in the absence of coronary artery stenosis [23][24][25][26]. An inverse relation between hyperemic myocardial blood flow and fasting insulin level has also been found among healthy, nonobese individuals, which suggests that even mild insulin resistance is associated with impaired coronary flow reserve [27].…”

Section: Tissue Perfusionmentioning

confidence: 99%

Obesity and diabetes: An update

Verma

Hussain

2017

Diabetes & Metabolic Syndrome: Clinical Research & Revi

219

149

View full text Add to dashboard Cite

“…et al, 2000), cardiopathy (Alan and Karin, 2009) and retinopathy (Romero-Aroca et al, 2009). Therefore, numerous therapies in diabetes have been developed to maintain the normal blood glucose level by means of ␣-glucosidase inhibitors (Ye et al, 2002), angiotensin-converting enzyme inhibitors (ACEI) (Pitt et al, 2000;Kawata et al, 2006) and so on. Besides, a wealth of evidence indicates that the diabetic development and progression are associated with increased oxidative stress (AydIn et al, 2001;Sydow and Münzel, 2003).…”

Section: Introductionmentioning

confidence: 98%